We are a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases with first-in-class nanotherapeutics. Our science harnesses the extraordinary properties of elemental nanocrystals for therapeutic use.
Our nanotherapeutics target cellular energy impairments that are common to many diseases. This novel approach has allowed us to explore broad applications of our drugs across therapeutic areas.
We believe in applying innovations to therapeutic challenges that currently have no effective solutions. With the right mix of experience, expertise, and creativity, we are changing the landscape of clinical development.
Our Clinical Trials
Results from the Phase 2 REPAIR clinical studies provided evidence for central nervous system target engagement of Clene’s lead therapeutic candidate, CNM-Au8®, a gold nanocrystal suspension, in the brains of both Multiple Sclerosis (MS) and Parkinson’s Disease (PD) patients.